Salute e Benessere
Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
The review, entitled , was an invited contribution from the editorial team at HVI for inclusion in their special edition on cancer vaccines. The Company co-authored the review in close collaboration with senior academics from the University of Oxford's cancer vaccine programme. The article describes the history of cancer vaccine development, the impact of the SARS-CoV-2 pandemic on vaccine immunology, and the hurdles that face the successful clinical development of vaccines within the solid tumour space.
Limited understanding of tumour biology has historically been a major obstacle to progress in cancer vaccine development. Following the announcement of its £12.8m seed funding round in April 2024 , Infinitopes is investing in world-leading mass spectrometry equipment to accurately identify the best synergistic tumour targets. This will enable the company to expand the development of its precision-targeted cancer vaccines for five further cancers beyond its lead candidate, which is due to begin phase I/IIa later this year.
is available to read online at:
https://www.tandfonline.com/doi/10.1080/21645515.2024.2331486
Infinitopes Ltd is a soon to be clinical stage, integrated cancer biotechnology company supported by Cancer Research UK (CRUK) and the University of Oxford . The Company combines two world leading platforms, in precision antigen discovery and in high efficiency, vector delivery systems, to develop immunologically durable vaccines for use against multiple solid tumour indications. The lead vaccine candidate is expected to begin phase I/IIa trials in Q3 2024. Infinitopes has cultivated in-house talent across antigen discovery, immunology, vaccinology, oncology, biomanufacturing, trials and regulation, winning an 'Innovative Licensing and Access Pathway' (ILAP) innovation passport from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in 2022. Infinitopes has also won two prestigious, maximum size nondilutive awards from Innovate UK, a Cancer Therapeutics Award (in 2022) and a Future Economy Investor Partnership (in 2023). In 2024, the company closed its £12.8 m seed financing. Since incorporation, the Infinitopes team has grown from three co-founders to 28 full time equivalents, and is now the largest tenant of Oxford University's BioEscalator Innovation Building. For more information, visit www.infinitopes.com
View original content: https://www.prnewswire.co.uk/news-releases/infinitopes-article-in-peer-reviewed-journal-seeks-to-unlock-the-potential-of-cancer-vaccines-302140354.html